RH

Russell Howard

Immutep Limited | Non-Executive Chairman, Non-Executive Director
Dr Howard has been a Non-Executive Director of Immutep since May 8, 2013 and has been appointed as Non-Executive Chairman on November 17, 2017. He is an Australian scientist, executive manager and entrepreneur. He was a pioneer in molecular parasitology and commercialization of 'DNA Shuffling'. He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr. Howard worked at Schering-Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc. After its spin-out from GlaxoWellcome, as Maxygen's CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising US$ 260.0 million. Maxygen developed and partnered dozens of technology applications and products over 12 years of his tenure as CEO. After leaving Maxygen in 2008, he started the Cleantech company Oakbio Inc. (dba NovoNutrients) and remains involved in several innovative companies in the USA and Australia. He is a member of Risk Committee.

Company and Roles

Company
Title
Tenure
Since
IMM
Immutep Limited
  • Non-Executive Chairman
  • Non-Executive Director
11yrs, 9mthMay 2013

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
IMM
Immutep Limited
06/12/2401,417,977N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
IMM
Immutep Limited
06/12/24
Exercise
304,770$0.330$100,574Conversion of securities
IMM
Immutep Limited
06/12/24
Issued
304,770$0.330$100,574Conversion of securities
IMM
Immutep Limited
23/11/23
Issued
178,356$0.295$52,615Director remuneration
IMM
Immutep Limited
21/12/22
Issued
113,207$0.290$32,830Conversion of securities
IMM
Immutep Limited
21/12/22
Exercise
113,207$0.290$32,830Conversion of securities